Timely detection and treatment benefits patients with scleroderma‑associated interstitial lung disease and the physicians who treat them.
When considering a lung transplant for a patient with rheumatic lung disease, the multi-system nature of the disease can significantly increase complexity.
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
The SENSCIS® study, co-led by Cleveland Clinic’s Kristin Highland, MD, explores the use of nintedanib in patients with scleroderma-associated interstitial lung disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A man presents with myalgias, skin thickening in his arms, legs and abdomen and stiffness in his joints. The Director of the Scleroderma Program develops the differential.
Laparoscopic RYGB may become the preferred approach to decrease acid and bile reflux and preserve esophageal function in scleroderma patients.
To clarify conflicting reports on the incidence of breast cancer in SSc, a research team studies the development of breast cancer in SSc patients and compares them with a nonscleroderma cohort of breast cancer patients.
Skin thickening figures prominently in almost all cases of systemic sclerosis. Effective treatments are scarce, but not for lack of investigations of new options. Here’s a rundown of the most promising.
Here’s stark visual evidence of why skin thickness may be the most debilitating aspect of a condition whose name comes from the Greek for “hard skin.”
Decisions about complex rheumatic conditions often must be based on expert opinions alone if RCTs aren’t available, especially when pulmonary disease is involved. Here’s how a combined rheumatology-pulmonary clinic can help.